The private operator switched to loss in 2025, reporting a negative result of nearly RON4 million.
The pro-forma consolidated turnover reached over RON3.17 billion (approximately EUR630 million), up by almost 17% compared to 2024, while the pro-forma EBITDA reached RON459 million in 2025.
The increase in turnover and operational volumes reflects not only MedLife’s resilience, but also its relevance for the health of Romanians in diverse economic contexts. Since its listing on the Bucharest Stock Exchange in 2016, MedLife has recorded an average annual growth of over 20%, consolidating its position as one of the most dynamic Romanian entrepreneurial companies.
In 2025, the hospital division recorded a 27% increase compared to the previous year in terms of the number of hospitalizations, reaching over 200 thousand, laboratories processed over 10 million investigations, and clinics accumulated almost 5 million visits. Among the most requested services were consultations in gynecology, cardiology, advanced imaging (MRI, CT), complex laboratory tests and minimally invasive surgeries.
This evolution reflects MedLife’s integrated model, in which patients benefit from continuity between diagnosis, treatment and long-term medical prevention.
“In addition to increasing operational volumes, MedLife has strengthened its network and brought innovation closer to patients. The acquisitions of MEDSTAR Cluj-Napoca and Routine Med Tulcea, as well as the entry into the market in the Republic of Moldova through All Clinic, have expanded access to integrated medical services, while the new emergency room at MedLife Medical Park has provided patients with emergency services at the highest standards. In 2025, MedLife launched the first AI assistant integrated into the application, inaugurated the Center of Excellence in Pelvic Neurosurgery, the first in South-Eastern Europe, and the first fully automated laboratory in Brasov, also introducing the EarlyCDT® test for the early detection of lung cancer. In Timisoara, robotics and AI have joined with human expertise in a center of excellence dedicated to orthopedics, and investments in Pitesti and Craiova have brought a new hyperclinic and a modern operating room,” the report reads.
In parallel, in genomics, MedLife has started with cutting-edge large-scale genetic testing programs, such as Longevity 100+ and investments in advanced sequencing technology, aimed at bringing preventive and personalized medicine closer to patients.
“We believe that the future of medicine lies in data, technology and prevention. Our genomic research approach is the expression of this vision. A project that opens paths, puts Romania on the map of genomic research and creates the premises for a paradigm shift in medicine, based on a personalized approach to the patient and a proactive therapeutic action”, said Mihai Marcu, CEO & President of the Board of Directors of MedLife Group.
Plans for 2026: medicine of the future, closer to the patient
In 2026, MedLife’s first major initiative is to bring genetic testing under the Longevity 100+ program to a large scale, providing patients with access to personalized prevention and diagnosis.
The Group will continue to explore strategic growth opportunities through acquisitions, especially in complementary areas such as aesthetics, sports and wellness, with the aim of strengthening integrated services.
In parallel, MedLife will focus on the development of niche centers, opening new horizons for specialized medicine and personalized services.
The integration of artificial intelligence, digital technologies and robotics will become part of the daily way of working, supporting doctors’ decisions and facilitating a complete medical act, in which innovation is combined with the experience and expertise of specialists.
Through all these actions, MedLife reaffirms its vision: a medicine that puts the patient at the center of attention, supported by technology and innovation, without losing the essential link between patient and doctor.
“The economy is adjusting, and companies are feeling these changes. Consumption slowed down slightly, especially in the last quarter of 2025, but health remains a constant priority for Romanians. MedLife’s results remained solid, even in a challenging economic context. We believe that the recent measures are starting to take effect and the economy will return to a positive trend. We look to the future with moderate optimism. The private sector continues to demonstrate its resilience: companies work, invest and actively contribute to the economy, even in difficult conditions,” added Mihai Marcu.
The Group will continue to explore strategic growth opportunities through acquisitions, especially in complementary areas such as aesthetics, sports and wellness, with the aim of strengthening integrated services,” the report reads.
MedLife Group is 12.8%-owned by Mihail Marcu, 14% by Mihaela Gabriela Cristescu and 13.2% by Fondul de Pensii Administrat Privat NN Pensii, per stock market data. The company has a market capitalization of RON7.3 billion.